|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The role of P-glycoprotein (MDR1) polymorphisms and mutations in colorectal cancer.
|
11678332 |
2001 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas.
|
9337699 |
1997 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Differences in ABCB1 (1236C>T) and ABCB1 (2677G>T/A) genotypes and T(1236) allele distribution between investigated populations indicate significant impact of these SNPs on risk of development of colorectal cancer.
|
19415305 |
2009 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases.
|
8898977 |
1996 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The ABCB1 polymorphisms might be a candidate pharmacogenomic factor to assess susceptibility and prognosis after oxaliplatin-based chemotherapy for CRC patients.
|
23746184 |
2013 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The expression of cytochrome P450 2C19 (CYP2C19) and ATP-binding cassette, sub-family B member 1 (ABCB1) were significantly lower in the EREC group (6/15) compared to the NREC group (9/15) in colorectal cancer with metachronous liver metastasis and with serum CEA >5 ng/ml.
|
27127120 |
2016 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated the consequences of ABCB1/MDR1 loss-of-function in a common murine model for CAC (AOM/DSS).
|
28686677 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further studies on herbal medicines with demonstrated effects against P-gp overexpression will aid in improving the efficacy of chemotherapy in CRC.
|
30158992 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer.
|
19192650 |
2009 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CRC risk associated with ever MHT use as well as with duration was significantly modified by rs1202168 in the transporter gene ABCB1 (P interaction=0.04).
|
21490239 |
2011 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Combined PC and CRC signature or "combined cancer signature" was derived to differentiate either CRC and PC from controls (MDR1, SRBC, VHL, MUC2, RB1, SYK and GPC3) AUC = 0.8177, Sens = 0.6316 Spec = 0.840.
|
24288256 |
2014 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the ABC transporters P-glycoprotein/multidrug resistance 1 and BRCP, in cooperation with IL-10, are involved in the biological mechanism underlying the protective effect of fiber intake in relation to CRC.
|
26109419 |
2015 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers.
|
9330605 |
1997 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
JJR reversed multidrug resistance and enhanced the sensitivity to chemotherapy, which could be attributed to the down-regulation of COX-2 in MDR1/P-gp-mediated MDR colorectal cancer after chemotherapy.
|
23543356 |
2014 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
P-glycoprotein (P-gp) is a 170 kDa transmembrane glycoprotein which plays a significant role in modulating pleomorphic or multiple drug resistance (MDR) in a wide variety of human cancers like renal and colorectal carcinoma.
|
10630353 |
1999 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we showed that PIK3CA and PIK3CB are upregulated in CRCs and positively correlated with MDR-1, LRP, and GST-π.
|
26747178 |
2016 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features.
|
11323103 |
2001 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the present study, 146 Bulgarian patients with sporadic colorectal cancer and 160 healthy Bulgarian volunteers were evaluated for the two polymorphisms in MDR1.
|
17674045 |
2008 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, our data show that EGCG may be act as a novel chemo-sensitizer, and the GRP78/NF-κB/miR-155-5p/MDR1 pathway plays a vital role in EGCG enhancing the sensitivity of colorectal cancer to 5-FU.
|
30741544 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
P-Glycoprotein 1 Affects Chemoactivities of Resveratrol against Human Colorectal Cancer Cells.
|
31487863 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
|
25691056 |
2015 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genotyping of SNPs in the ABCB1 gene prior to chemotherapy administration could help reduce adverse reactions in colorectal cancer patients.
|
21142915 |
2010 |
|
Colorectal Carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Wide-type p53 gene has a remarkable reversal activity for the high expression of MDR1 gene in colorectal cancers.
|
15222051 |
2004 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
While expression levels of Nrf2 and ABCB1 (P-gp) were markedly higher in both mRNA and protein levels in CRC biopsies (p < 0.01), Keap1 expression level was significantly lower in these samples (p < 0.05).
|
29793178 |
2018 |